The impact of 18F-FDG PET/CT in the clinical management of patients with lymph node metastasis of unknown primary origin.

The impact of 18F-FDG PET/CT in the clinical management of patients with lymph node metastasis of unknown primary origin. Neoplasma. 2020 Sep 04;: Authors: Nikolova PN, Hadzhiyska VH, Mladenov KB, Ilcheva MG, Veneva S, Grudeva VV, Dineva SE, Asenov YN Abstract The aim of this study was to evaluate the diagnostic performance and the utility of F-18-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) in the clinical management of patients presenting with lymph node metastasis of undefined primary origin (CUP). A total of 53 patients (34 males, 19 females) with a diagnosis of lymph node metastasis according to the histopathology and/or conventional imaging were enrolled in this retrospective study. Patients were divided into four groups according to the initial location of their metastasis - group 1, cervical lymph nodes (n = 39), group 2, axillary lymph nodes (n = 6), group 3, mediastinal lymph nodes (n = 2) and group 4, abdominal and pelvic lymph nodes (n = 6). The site of a probable primary malignancy suggested by PET/CT was confirmed by biopsy/further investigations or follow-up. 18F-FDG PET/CT accurately detected the primary carcinoma in 19 of 53 patients (36%), with head and neck cancer and lung carcinoma being the most common primary locations. The PET-CT scan results were negative for primary site localization in 13% of patients (false-negative), while 45% had true negative results, and 6% displaye...
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research